Heat Biologics, Inc.
HTBXAMEXHealthcare
$2.38
+$0.01(+0.42%)
Market Cap$61074370
P/E Ratio—
52W High$2.48
52W Low$2.33
Heat Biologics, Inc. (HTBX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HTBX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2022Report Date: May 16, 2022EPS Actual
-$0.32
Est. -$0.49 · +33.7%
Revenue
$0.00B
Fiscal Period
Q2 FY2022
FY ends December
Report Date
May 16, 2022
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
HTBX reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q2 FY2022 | May 16, 2022 | -$0.49 | -$0.32 | +33.7% | $0.00B | — | — |
| ▼ Q1 FY2022 | Mar 11, 2022 | -$0.32 | -$0.54 | -68.8% | $-0.00B | $0.00B | -199.4% |
| — Q4 FY2021 | Nov 10, 2021 | -$0.30 | -$0.30 | +0.0% | $0.00B | $0.00B | +3.6% |
| ▲ Q3 FY2021 | Aug 11, 2021 | -$0.30 | -$0.26 | +13.3% | $0.00B | $0.00B | -23.4% |
| ▼ Q2 FY2021 | May 5, 2021 | -$0.29 | -$0.31 | -6.9% | $0.00B | — | — |
| ▲ Q1 FY2021 | Mar 25, 2021 | -$0.35 | -$0.02 | +94.3% | $0.00B | — | — |
| ▼ Q4 FY2020 | Nov 9, 2020 | -$0.23 | -$0.42 | -82.6% | $0.00B | — | — |
| ▲ Q3 FY2020 | Aug 7, 2020 | -$0.66 | -$0.35 | +47.0% | $0.00B | $0.00B | -44.4% |
Q2 FY2022
May 16, 2022Beat
EPS Actual
-$0.32
EPS Est.
-$0.49
EPS Surpr.
+33.7%
Revenue
$0.00B
Q1 FY2022
Mar 11, 2022Miss
EPS Actual
-$0.54
EPS Est.
-$0.32
EPS Surpr.
-68.8%
Revenue
$-0.00B
Q4 FY2021
Nov 10, 2021
EPS Actual
-$0.30
EPS Est.
-$0.30
EPS Surpr.
+0.0%
Revenue
$0.00B
Q3 FY2021
Aug 11, 2021Beat
EPS Actual
-$0.26
EPS Est.
-$0.30
EPS Surpr.
+13.3%
Revenue
$0.00B
Q2 FY2021
May 5, 2021Miss
EPS Actual
-$0.31
EPS Est.
-$0.29
EPS Surpr.
-6.9%
Revenue
$0.00B
Q1 FY2021
Mar 25, 2021Beat
EPS Actual
-$0.02
EPS Est.
-$0.35
EPS Surpr.
+94.3%
Revenue
$0.00B
Q4 FY2020
Nov 9, 2020Miss
EPS Actual
-$0.42
EPS Est.
-$0.23
EPS Surpr.
-82.6%
Revenue
$0.00B
Q3 FY2020
Aug 7, 2020Beat
EPS Actual
-$0.35
EPS Est.
-$0.66
EPS Surpr.
+47.0%
Revenue
$0.00B
No analyst estimates available for HTBX.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2022 | May 16, 2022 | +33.7% | $2.38 | — | — |
| ▼ Q1 FY2022 | Mar 11, 2022 | -68.8% | $2.44 | $2.34 | -4.10% |
| ▲ Q4 FY2021 | Nov 10, 2021 | +0.0% | $5.29 | $5.16 | -2.46% |
| ▲ Q3 FY2021 | Aug 11, 2021 | +13.3% | $6.55 | $6.63 | +1.22% |
| ▼ Q2 FY2021 | May 5, 2021 | -6.9% | $6.74 | $6.67 | -1.04% |
| ▲ Q1 FY2021 | Mar 25, 2021 | +94.3% | $7.60 | $7.74 | +1.84% |
| ▼ Q4 FY2020 | Nov 9, 2020 | -82.6% | $7.98 | $7.21 | -9.65% |
| ▲ Q3 FY2020 | Aug 7, 2020 | +47.0% | $14.77 | $15.19 | +2.84% |
Q2 FY2022—
Report Date
May 16, 2022
EPS Beat/Miss
+33.7%
Price Before
$2.38
Price After
—
Q1 FY2022-4.10%
Report Date
Mar 11, 2022
EPS Beat/Miss
-68.8%
Price Before
$2.44
Price After
$2.34
Q4 FY2021-2.46%
Report Date
Nov 10, 2021
EPS Beat/Miss
+0.0%
Price Before
$5.29
Price After
$5.16
Q3 FY2021+1.22%
Report Date
Aug 11, 2021
EPS Beat/Miss
+13.3%
Price Before
$6.55
Price After
$6.63
Q2 FY2021-1.04%
Report Date
May 5, 2021
EPS Beat/Miss
-6.9%
Price Before
$6.74
Price After
$6.67
Q1 FY2021+1.84%
Report Date
Mar 25, 2021
EPS Beat/Miss
+94.3%
Price Before
$7.60
Price After
$7.74
Q4 FY2020-9.65%
Report Date
Nov 9, 2020
EPS Beat/Miss
-82.6%
Price Before
$7.98
Price After
$7.21
Q3 FY2020+2.84%
Report Date
Aug 7, 2020
EPS Beat/Miss
+47.0%
Price Before
$14.77
Price After
$15.19
Avg Beat Reaction+0.86%
Avg Miss Reaction-4.93%
Beat Rate5 / 8 quarters
Largest Move-9.65% (Q4 FY2020)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HTBX ends December
Heat Biologics, Inc. (HTBX) most recently reported earnings on May 16, 2022 for Q2 FY2022, posting EPS of $-0.32 — beating the analyst consensus of $-0.49 by +33.7%. The next HTBX earnings date is expected around September 1, 2026.
Each quarter, investors track HTBX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HTBX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HTBX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HTBX earnings · 5 questionsHeat Biologics, Inc.'s next earnings report is expected around September 1, 2026. HTBX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HTBX historically reports after market close (AMC).
HTBX earnings datewhen is HTBX earningsHTBX next earnings datewhen does HTBX report earningsHTBX earnings calendar
▸ Source: FMP · Heat Biologics, Inc. SEC filings · US GAAP · Heat Biologics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026